Treatment progress of chronic lymphocytic leukemia: reports from the 57th American Society of Hematology annual meeting
10.3760/cma.j.issn.1009-9921.2016.01.009
- VernacularTitle:慢性淋巴细胞白血病治疗进展:第57届美国血液学会年会报道
- Author:
Yue LI
;
Wei XU
;
Jianyong LI
- Publication Type:Journal Article
- Keywords:
Leukemia;
lymphocytic;
chronic;
American Society of Hematology annual meeting
- From:
Journal of Leukemia & Lymphoma
2016;25(1):29-32
- CountryChina
- Language:Chinese
-
Abstract:
Chronic lymphocytic leukemia (CLL) is a chronic B-cell lymphoproliferative clonal disease with a highly heterogeneous clinical course. In recent years, with the emerging of immunochemotherapy, bcl-2 inhibitor, B-cell receptor signal transduction kinase inhibitors and the chimeric antigen receptor-T cell (CAR-T), more and more improvements were made in CLL therapy and remission. This report addressed the progress of CLL therapy in the 57th American Society of Hematology annual meeting.
